Arzerra ofatumumab: Updated Phase III data

Updated data from an open-label Phase III trial in 95 patients refractory to fludarabine and alemtuzumab showed that ofatumumab produced an objective response rate (ORR) of

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE